The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice

被引:120
作者
Wang, Xingxu [1 ]
Ye, Yong [1 ]
Gong, Hui [1 ]
Wu, Jian [1 ]
Yuan, Jie [1 ]
Wang, Shijun [1 ]
Yin, Peipei [2 ]
Ding, Zhiwen [2 ]
Kang, Le [1 ]
Jiang, Qiu [2 ]
Zhang, Weijing [2 ]
Li, Yang [2 ]
Ge, Junbo [1 ,2 ]
Zou, Yunzeng [1 ,2 ]
机构
[1] Fudan Univ, Zhongshan Hosp, Shanghai Inst Cardiovasc Dis, Shanghai 200032, Peoples R China
[2] Fudan Univ, Inst Biomed Sci, Shanghai 200032, Peoples R China
基金
中国国家自然科学基金;
关键词
Angiotensin II type 1-receptor blockers; Pressure overload; Mechanical stretch; Cardiac hypertrophy; Heart failure; EXPERIMENTAL AUTOIMMUNE MYOCARDITIS; CONVERTING ENZYME 2; ENDOPLASMIC-RETICULUM STRESS; HEART-FAILURE; HYPERTENSIVE-RATS; ALDOSTERONE SYSTEM; 1-7/MAS RECEPTOR; BLOOD-PRESSURE; MAS RECEPTOR; AXIS;
D O I
10.1016/j.yjmcc.2016.05.012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Angiotensin II (AngII) type 1 receptor blockers (ARBs) have been effectively used in hypertension and cardiac remodeling. However, the differences among them are still unclear. We designed this study to examine and compare the effects of several ARBs widely used in clinics, including Olmesartan, Candesartan, Telmisartan, Losartan, Valsartan and Irbesartan, on the ACE-AngII-AT1 axis and the ACE2-Ang(1-7)-Mas axis during the development of cardiac remodeling after pressure overload. Although all of the six ARBs, attenuated the development of cardiac hypertrophy and heart failure induced by transverse aortic constriction (TAC) for 2 or 4 weeks in the wild-type mice evaluated by echocardiography and hemodynamic measurements, the degree of attenuation by Olmesartan, Candesartan and Losartan tended to be larger than that of the other three drugs tested. Additionally, the degree of downregulation of the ACE-AngII-AT1 axis and upregulation of the ACE2-Ang(1-7)-Mas axis was higher in response to Olmesartan, Candesartan and Losartan administration in vivo and in vitro. Moreover, in angiotensinogen-knockdown mice, TAC-induced cardiac hypertrophy and heart failure were inhibited by Olmesartan, Candesartan and Losartan but not by Telmisartan, Valsartan and Irbesartan administration. Furthermore, only Olmesartan and Candesartan could downregulate the ACE-AngII-AT1 axis and upregulate the ACE2Ang(1-7)-Mas axis in vitro. Our data suggest that Olmesartan, Candesartan and Losartan could effectively inhibit pressure overload-induced cardiac remodeling even when with knockdown of Ang II, possibly through upregulation of the expression of the ACE2-Ang(1-7)-Mas axis and downregulation of the expression of the ACE-AngII-AT1 axis. In contrast, Telmisartan, Valsartan and Irbesartan only played a role in the presence of AngII, and Losartan had no effect in the presence of AngIIn vitro. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:180 / 190
页数:11
相关论文
共 50 条
[1]   Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme [J].
Agata, Jun ;
Ura, Nobuyuki ;
Yoshida, Hideaki ;
Shinshi, Yasuyuki ;
Sasaki, Haruki ;
Hyakkoku, Masaya ;
Taniguchi, Shinya ;
Shimamoto, Kazuaki .
HYPERTENSION RESEARCH, 2006, 29 (11) :865-874
[2]   Candesartan cilexetil protects from cardiac myosin induced cardiotoxicity via reduction of endoplasmic reticulum stress and apoptosis in rats: Involvement of ACE2-Ang (1-7)-mas axis [J].
Arumugam, Somasundaram ;
Thandavarayan, Rajarajan A. ;
Palaniyandi, Suresh S. ;
Giridharan, Vijayasree V. ;
Arozal, Wawaimuli ;
Sari, Flori R. ;
Soetikno, Vivian ;
Harima, Meilei ;
Suzuki, Kenji ;
Kodama, Makoto ;
Watanabe, Kenichi .
TOXICOLOGY, 2012, 291 (1-3) :139-145
[3]   Constitutively Active Mutant N111G of Angiotensin II Type 1 (AT1) Receptor Induces Homologous Internalization Through Mediation of AT1-Receptor Antagonist [J].
Bhuiyan, Mohiuddin Ahmed ;
Hossain, Murad ;
Miura, Shin-ichiro ;
Nakamura, Takashi ;
Ozaki, Masanobu ;
Nagatomo, Takafumi .
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2009, 111 (03) :227-234
[4]   Angiotensin-converting enzyme 2 is an essential regulator of heart function [J].
Crackower, MA ;
Sarao, R ;
Oudit, GY ;
Yagil, C ;
Kozieradzki, I ;
Scanga, SE ;
Oliveira-dos-Santos, AJ ;
da Costa, J ;
Zhang, LY ;
Pei, Y ;
Scholey, J ;
Ferrario, CM ;
Manoukian, AS ;
Chappell, MC ;
Backx, PH ;
Yagil, Y ;
Penninger, JM .
NATURE, 2002, 417 (6891) :822-828
[5]   Detection of soluble angiotensin-converting enzyme 2 in heart failure [J].
Epelman, Slava ;
Tang, W. H. Wilson ;
Chen, Stephen Y. ;
Van Lente, Frederick ;
Francis, Gary S. ;
Sen, Subha .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (09) :750-754
[6]   Single mutations at Asn295 and Leu305 in the cytoplasmic half of transmembrane α-helix domain 7 of the AT1 receptor induce promiscuous agonist specificity for angiotensin II fragments:: A pseudo-constitutive activity [J].
Feng, YH ;
Zhou, LY ;
Qiu, RD ;
Zeng, R .
MOLECULAR PHARMACOLOGY, 2005, 68 (02) :347-355
[7]   Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2 [J].
Ferrario, CM ;
Jessup, J ;
Chappell, MC ;
Averill, DB ;
Brosnihan, KB ;
Tallant, EA ;
Diz, DI ;
Gallagher, PE .
CIRCULATION, 2005, 111 (20) :2605-2610
[8]   Effect of anti hypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men [J].
Fogari, R ;
Preti, P ;
Derosa, G ;
Marasi, G ;
Zoppi, A ;
Rinaldi, A ;
Mugellini, A .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 58 (03) :177-180
[9]   Chronic inhibition of cGMP-specific phosphodiesterase 5 suppresses endoplasmic reticulum stress in heart failure [J].
Gong, Wei ;
Duan, Quanlu ;
Cai, Zhejun ;
Chen, Chen ;
Ni, Li ;
Yan, Mengwen ;
Wang, Xingxu ;
Cianflone, Katherine ;
Wang, Dao Wen .
BRITISH JOURNAL OF PHARMACOLOGY, 2013, 170 (07) :1396-1409
[10]   Effects of angiotensin II type 1 receptor antagonist on nitric oxide synthase expression and myocardial remodeling in goldblatt hypertensive rats [J].
Higashi, T ;
Kobayashi, N ;
Hara, K ;
Shirataki, H ;
Matsuoka, H .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2000, 35 (04) :564-571